MULTIPLE MYELOMA PATIENTS THAT DEVELOP SECOND PRIMARY MALIGNANCY HAVE A WORSE PROGNOSIS THAN MULTIPLE MYELOMA PATIENTS TREATED BEFORE THE INTRODUCTION OF NOVEL AGENTS: A POPULATION BASED-STUDY

被引：0
|
作者：
Jonsdottir, G. [1 ]
Lund, S. H. [1 ]
Landgren, O. [2 ,3 ,4 ]
Bjorkholm, M. [2 ,3 ]
Turesson, I. [5 ]
Wahlin, A. [6 ]
Blimark, C. [7 ]
Hultcrantz, M. [2 ,3 ]
Porwit, A. [8 ]
Kristinsson, S. Y. [1 ,2 ,3 ]
机构：
[1] Univ Iceland, Fac Med, Reykjavik, Iceland
[2] Karolinska Univ Hosp, Div Hematol, Dept Med, Stockholm, Sweden
[3] Karolinska Inst, Stockholm, Sweden
[4] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[5] Skane Univ Hosp, Dept Hematol & Coagulat Disorders, Malmo, Sweden
[6] Umea Univ, Dept Radiat Sci, Umea, Sweden
[7] Sahlgrens Univ Hosp, Sect Hematol & Coagulat, Dept Med, Gothenburg, Sweden
[8] Toronto Gen Hosp, Dept Lab Med & Pathobiol, Univ Hlth Network, Toronto, ON, Canada
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P378
引用
收藏
页码：116 / 117
页数：2
相关论文
共 50 条
  • [1] Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
    P Razavi
    K A Rand
    W Cozen
    A Chanan-Khan
    S Usmani
    S Ailawadhi
    Blood Cancer Journal, 2013, 3 : e121 - e121
  • [2] Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
    Razavi, P.
    Rand, K. A.
    Cozen, W.
    Chanan-Khan, A.
    Usmani, S.
    Ailawadhi, S.
    BLOOD CANCER JOURNAL, 2013, 3 : e121 - e121
  • [3] Observations of Second Primary Malignancy in Patients With Multiple Myeloma
    Ormerod, Anne
    Fausel, Christopher A.
    Abonour, Rafat
    Kiel, Patrick J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (02): : 113 - 117
  • [4] A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
    Dimopoulos, Meletios A.
    Richardson, Paul G.
    Brandenburg, Nancy
    Yu, Zhinuan
    Weber, Donna M.
    Niesvizky, Ruben
    Morgan, Gareth J.
    BLOOD, 2012, 119 (12) : 2764 - 2767
  • [5] Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study
    Jonsdottir, Gudbjorg
    Lund, Sigrun H.
    Bjorkholm, Magnus
    Turesson, Ingemar
    Wahlin, Anders
    Mailankody, Sham
    Blimark, Cecilie
    Hultcrantz, Malin
    Porwit, Anna
    Landgren, Ola
    Kristinsson, Sigurdur Y.
    HAEMATOLOGICA, 2016, 101 (04)
  • [6] Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
    Blimark, Cecilie
    Holmberg, Erik
    Mellqvist, Ulf-Henrik
    Landgren, Ola
    Bjoekholm, Magnus
    Hultcrantz, Malin
    Kjellander, Christian
    Turesson, Ingemar
    Kristinsson, Sigurdur Y.
    HAEMATOLOGICA, 2015, 100 (01) : 107 - 113
  • [7] Variable Risk of Second Primary Malignancy In Multiple Myeloma Patients of Different Ethnicities
    Razavi, Pedram
    Patel, Gaurav
    Chanan-Khan, Asher
    Ailawadhi, Sikander
    BLOOD, 2011, 118 (21) : 311 - 312
  • [8] Novel agents have a significant impact on survival of patients with multiple myeloma
    Lamm, Wolfgang
    Eder, Sandra
    Bojic, Marija
    Zielinski, Christoph C.
    Drach, Johannes
    WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 (3-4) : 92 - 97
  • [9] Novel agents have a significant impact on survival of patients with multiple myeloma
    Lamm, W.
    Eder, S.
    Gruber, M.
    Zielinski, C.
    Drach, J.
    ONKOLOGIE, 2011, 34 : 155 - 155
  • [10] Increased Incidence of a Second Lymphoproliferative Malignancy in Patients with Multiple Myeloma - a SEER based Study
    Chakraborty, Subhankar
    Hauke, Ralph J.
    Bonthu, Neelima
    Tarantolo, Stefano R.
    ANTICANCER RESEARCH, 2012, 32 (10) : 4507 - 4515
12345